San Antonio building has the capability to conduct euglycemic and insulin-clamp studies.

Cetero Research says that it has expanded its San Antonio, TX, operations. The site has a new 100-bed facility designed to run clinical pharmacology studies in healthy, diabetic, and obese participants.

The site has conducted clinical studies for more than 25 years, according to Sherwyn Schwartz, M.D., CEO of Cetero’s San Antonio facility. “One notable expansion is increased capacity to perform euglycemic and insulin-clamp studies. These specialized studies are ideal for establishing proof-of-concept for novel compounds or even comparing compounds to show superiority or equivalence.”

The facility is located on the Christus Santa Rosa Medical Campus and adjacent to one of the largest endocrinology practices in the country that sees more than 6,500 patients per month. In addition to a large database of normal healthy participants, type 1 and type 2 diabetics, and obese patients, Cetero also has access to patients with hypogonadism, neuropathy, osteoporosis, and erectile dysfunction.


Previous articleAbraxis Divests Everything Except Abraxane Franchise to Spinout
Next articleRecently Spun Out Axikin Obtains $3M Series A Financing